$20M–$50M

Revelstoke Capital Partners is a Denver-based private equity firm focused on building industry-leading companies in the healthcare and related business services sectors. The firm partners with entrepreneurs and management teams to execute a disciplined organic and acquisition growth strategy, aiming to build exceptional companies. Since its inception in 2013, Revelstoke has raised over $2.3 billion in equity and completed 65 acquisitions, including 17 platform companies and 48 add-on acquisitions.

Bessemer Venture Partners is a leading venture capital firm that partners with entrepreneurs from their early days through every stage of growth. With a history rooted in the Carnegie Steel empire, Bessemer has a long tradition of investing in transformative companies across various industries. The firm is committed to supporting entrepreneurs with capital, strategic guidance, and a robust network to build enduring companies.

SV Health Investors is a leading venture capital firm focused on investing in innovative healthcare companies. With a mission to transform healthcare one investment at a time, SV Health Investors supports diverse entrepreneurs in creating breakthrough companies and treatments. The firm has a strong track record of investing in companies that improve healthcare through innovative care delivery models, next-generation digital health technologies, and groundbreaking medical products. SV Health Investors is committed to diversity and believes that it strongly contributes to success.

Future Planet Capital is an impact-led venture capital firm based in the UK with a global reach. The firm focuses on investing in high-growth companies that address global challenges profitably, aligning with the UN Sustainable Development Goals. With over $400 million in assets under management and a portfolio of 140 companies, Future Planet Capital leverages its connections with top universities and research ecosystems to back innovative solutions in climate change, education, health, security, and sustainable growth.

Camino Real Capital Partners, LLC (CRCP) is a private investment firm based in Santa Fe, New Mexico, dedicated to investing in America's leading innovators and emerging technologies. The firm emphasizes building relationships, fostering growth opportunities, and creating value. CRCP focuses on transformative technology, emerging medical devices, life science innovations, and cutting-edge service providers in the energy sector. The firm invests its own capital alongside a network of accredited co-venturers, providing technology and marketing insights and management guidance to early-stage innovators.

Mitsui & Co. Global Investment, Inc. is a venture capital firm with over 20 years of experience, focusing on guiding entrepreneurs onto the global stage. The firm goes beyond financial support, offering strategic guidance and leveraging its vast network to facilitate key partnerships. With a commitment to improving human welfare, Mitsui partners with exceptional teams to reinvent industries worldwide.

Triangle Angel Partners (TAP) is an angel fund based in the Research Triangle Park area of North Carolina. Formed in 2011, TAP aims to leverage the expertise and capital of its members to support local entrepreneurs in high-tech start-ups. TAP provides not only financial investment but also mentoring, counseling, and access to a vast network of potential investors, customers, and strategic partners. The firm has launched two funds, TAP I and TAP II, with a focus on investing in companies within a half-day's drive of Research Triangle Park.

Black Diamond Ventures (BDV) is a transformational venture capital firm with over two decades of experience in hybrid investing. Founded by Chris Lucas, BDV focuses on multi-stage investments in biotech, deep tech, and med tech sectors, supporting visionary founders with strategic and operational guidance. The firm is committed to building relationships among investors and their investments, helping founders reach the next level through a network of partners and strategic opportunities.

MVM Partners LLP is a venture capital firm that has been investing in high-growth healthcare businesses since 1997. With a global presence in Boston, London, and the San Francisco Bay Area, MVM focuses on a broad range of healthcare sectors including medical technology, pharmaceuticals, diagnostics, contract research and manufacturing, and digital health. The firm collaborates with top management teams to bring innovative products to market, drive growth, and establish new standards of care in medicine.

Escalate Capital Partners is a prominent private credit and growth equity investment firm focusing on rapidly growing later-stage companies in the technology, software, services, and healthcare sectors. With a robust investment history, the firm has deployed $1.3 billion to accelerate growth while minimizing dilution for management and equity holders. The firm prides itself on providing stable and tailored capital solutions, backed by an experienced investment team with over 100 years of combined expertise, having invested over $2 billion in more than 500 companies.

City Side Ventures is a dynamic venture group established in 2015, focused on transforming early-stage capital deployment in Michigan. The firm is driven by experienced business builders, serial entrepreneurs, and technologists, aiming to elevate Michigan's startup ecosystem by building a network of innovative investors. City Side Ventures emphasizes investing in the 'driver' (the founder) rather than the 'car' (the business), and is committed to integrity, courage, impact, responsibility, and velocity in its operations.

Norwest Venture Partners is a multi-stage investment firm with a history of delivering top quartile returns over the past 60 years. The firm focuses on partnering with founder-managed or capital-efficient businesses, helping them scale from double-digit to triple-digit revenues. Norwest has navigated various economic cycles and remains committed to building strong relationships with its portfolio companies, emphasizing trust and cultural alignment.

GV, originally launched as Google Ventures in 2009, is a venture capital firm that operates independently with Alphabet as its sole limited partner. The firm focuses on supporting innovative founders at every stage of company-building, leveraging its access to Google's resources and expertise. With over $10 billion in assets under management, GV invests in a diverse range of industries, including technology, healthcare, and consumer products, and supports over 400 active portfolio companies across North America, Europe, and Israel.

LSG Investments is an evergreen venture fund dedicated to advancing healthcare by investing in early-stage life sciences technologies. The firm focuses on strengthening Pennsylvania's life sciences ecosystem and improving global healthcare outcomes. By providing early-stage capital and operational expertise, LSG Investments fosters company growth and job creation, bridging the gap between pre-seed and Series B funding.

NewSpring Capital is a private equity firm that partners with lower-middle market companies to create measurable value for business owners and Limited Partners. With over 25 years of experience, NewSpring focuses on fostering deep and enduring relationships, aligning goals and values with entrepreneurs, investors, and employees in pursuit of excellence. The firm manages over $3.5 billion across five distinct strategies, including growth equity, healthcare, mezzanine debt, holdings, and franchise investments. NewSpring is committed to accelerating growth and success for its portfolio companies through tailored capital solutions and strategic support.

RiverVest Venture Partners is a leading venture capital firm focused on building life science companies to address significant unmet medical needs. The firm is dedicated to improving the lives of patients, supporting entrepreneurs, and earning the trust of investors through science, strategy, and innovation. With a strong track record of successful investments and exits, RiverVest leverages its expertise to develop biopharma and medical device products that meet high, unmet medical needs, aiming for commercialization or IPO within three to five years of investment.